Login
$RZLT
$3.53 -$0.05 (1.4%) After hours

Company Executives

Officer Age Joined 2026 pay Source
Nevan Charles Elam Also a director
Chief Executive Officer and Acting Chairman of the Board
59 Not stated $5,711,410
Daron Evans
Chief Financial and Business Officer
53 2024 $2,285,466
Brian Roberts
Chief Medical Officer
52 2015 $2,564,957
Sunil Karnawat
Chief Commercial Officer
59 2025 $2,623,909

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
5 of 7
stated in the proxy
Average tenure
6.3 years
from year joined
CEO also chairs the board
Yes
Nevan Charles Elam
Director Age On board Independent Committees Other public boards 2026 pay Source
Nevan Charles Elam
59 2013
13 years
Not independent None stated Savara, Inc. Paid as CEO
Erik Harris
56 2025
1 year
Independent
Compensation Committee
None stated $353,286
Gil Labrucherie
55 2019
7 years
Independent
Audit Committee · Chair
None stated $373,286
Nerissa Kreher
54 2021
5 years
Independent
Compensation Committee Nominating and Governance Committee · Chair
Xeris Biopharma Holdings, Inc. $366,786
Philippe Fauchet
68 2020
6 years
Independent
Audit Committee
None stated $363,286
Wladimir Hogenhuis
62 2021
5 years
Independent
Audit Committee Compensation Committee · Chair
None stated $369,536
Young-Jin Kim
69 2019
7 years
Not independent None stated Genexine Inc. $346,036

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Oct 21, 2026
Handok
$5.0 million
July 2024

Purchase of 1,250,000 shares of common stock at $4.00 per share in the 2024 Private Placement

Handok
Amount not stated
May 2025

Purchase of 1,230,769 shares of common stock at $3.25 per share in the 2025 Private Placement; aggregate proceeds of this and the Nerissa Kreher purchase stated as $4.0 million

Nerissa Kreher
Amount not stated
May 2025

Purchase of 3,076 shares of common stock at $3.25 per share in the 2025 Private Placement

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support